Amneal Pharmaceuticals (AMRX) Return on Invested Capital (2018 - 2026)

Amneal Pharmaceuticals' Return on Invested Capital history runs 9 years deep, the most recent figure standing at 0.01% for Q1 2026.

• On a quarterly basis, Return on Invested Capital rose 1.0% year-over-year to 0.01% in Q1 2026; TTM through Mar 2026 was 0.01%, a 1.0% increase from a year earlier, with the FY2025 full-year figure at 0.06%, up 1.0% from the prior year.
• Return on Invested Capital climbed to 0.01% in Q1 2026 per AMRX's latest filing, from 0.01% in the prior quarter.
• Across five years, Return on Invested Capital topped out at 0.02% in Q3 2023 and bottomed at 0.01% in Q2 2022.
• The 5-year median for Return on Invested Capital is 0.01% (2025), against an average of 0.01%.
• Across the five-year window, Return on Invested Capital decreased 2 bps in 2022 and gained 3 bps in 2023, its largest moves.
• Year by year, Return on Invested Capital stood at 0.0% in 2022, then surged by 1998 bps to 0.02% in 2023, then sank by 62 bps to 0.01% in 2024, then soared by 52 bps to 0.01% in 2025, then gained by 24 bps to 0.01% in 2026.
• Per Business Quant, the three latest AMRX Return on Invested Capital figures stand at 0.01% (Q1 2026), 0.01% (Q4 2025), and 0.01% (Q3 2025).